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Research and development for neglected diseases: more is 
still needed, and faster
Neglected diseases, such as diarrhoeal diseases, malaria, 
tuberculosis, and neglected tropical diseases are rife 
where poverty prevails. Hundreds of millions of people 
living in rural and urban areas of resource-poor countries 
are aﬀ ected.1 According to data from the Global 
Burden of Disease Study 2010, the collective burden of 
neglected diseases is 248 million disability-adjusted 
life years (DALYs), and they caused 4 million deaths 
in 2010 (table).2,3 The Millennium Development Goals 
directly or indirectly address neglected diseases.4 The 
global strategy for the control of many of the neglected 
tropical diseases is preventive chemotherapy.5
Over the past 15 years, there has been unprecedented 
political and ﬁ nancial commitment to tackle neglected 
diseases, including the forging of new global alliances, 
non-proﬁ t public–private partnerships (eg, the 
Medicines for Malaria Venture and the Drugs for 
Neglected Diseases initiative [DNDi]), and massive 
scale-up of interventions enabled by multimillion 
dollar investments by philanthropic institutions (eg, 
the Bill & Melinda Gates Foundation) and development 
and cooperation agencies (eg, the UK Department for 
International Development).6 In this rapidly changing 
landscape for neglected diseases, the critical assessment 
and quantiﬁ cation of research and development 
activities is important.
In The Lancet Global Health, Belen Pedrique and 
colleagues7 provide new insight into the research 
and development pipeline of drugs and vaccines for 
neglected diseases in 2000–11. The investigators did a 
broad-based review of available databases, consisting 
of major drug regulatory authorities; the WHO List 
of Prequaliﬁ ed Medicinal Products, and the WHO 
Model List of Essential Medicines. Additionally, they 
established the number of registered phase 1–3 clinical 
trials of drugs for neglected diseases by examining the 
US National Institutes of Health clinical trial database 
and the WHO registry of clinical trials, including a 
snapshot of ongoing trials as of Dec 31, 2011.
Their main ﬁ ndings were as follows. Of 850 new 
therapeutic products registered in the past 12 years, 
37 (4%) had an indication for neglected diseases 
(table). Most of these products were classiﬁ ed as a 
new indication or formulation of existing entities 
(n=25), whereas only four (1%) of 336 products are 
new chemical entities (three for malaria and one for 
diarrhoeal diseases). And of about 150 000 clinical trials 
registered in late 2011, only 2016 (1%) are for neglected 
diseases. These ﬁ ndings are consistent with a previous 
analysis which showed that, of 1396 new chemical 
entities approved in 1975–99, only 16 (1%) were for 
neglected diseases.8 The contemporary drug and vaccine 
armamentarium for neglected diseases, therefore, 
remains insuﬃ  cient, and the situation has not much 
improved during the past 20–30 years. 
We fully agree with the investigators that this 
insuﬃ  ciency in the pipeline of new drugs for neglected 
diseases is of crucial concern and oﬀ er the following 
points for consideration. First, as we have emphasised 
elsewhere,9,10 action to develop new drugs for neglected 
diseases is needed more than ever because control 
eﬀ orts are being stepped up and there is therefore a 
risk of resistance development to the very few available 
drugs. A need exists to develop drugs and vaccines 
aimed at the most neglected among the neglected 
diseases. The Medicines for Malaria Venture and DNDi 
can serve as examples.11,12 Early on, these product 
development partnerships were praised as game 
changers to produce the drugs we need for neglected 
diseases.13 The slight quantitative improvement in new 
DALYs3
(thousands)
Deaths2
(thousands)
New therapeutic 
products7
Neglected diseases
Diarrhoeal diseases* 89 513 (4%) 1445·8 (3%) 7 (1%)
Malaria 82 685 (3%) 1169·5 (2%) 12 (1%)
Tuberculosis 49 396 (2%) 1196·0 (2%) 7 (1%)
NTDs† 21 330 (1%) 128·6 (<0·5%) 5 (1%)
Other 4724 (<0·5%) 23·7 (<0·5%) 6 (1%)
Subtotal 247 648 (10%) 3963·6 (8%) 37 (4%)
All causes 2 490 385 (100%) 52 769·7 (100%) 850 (100%)
Data are n (%). DALY=disability-adjusted life years. NTD=neglected tropical disease. *Includes cholera, Salmonella spp 
infections, shigellosis, enteropathogenic Escherichia coli infection, enterotoxigenic E coli infections, Campylobacter 
enteritis, amoebiasis, cryptosporidiosis, rotaviral enteritis, and other diarrhoeal diseases. †Includes Chagas disease, 
leishmaniasis, human African trypanosomiasis, schistosomiasis, cysticercosis, echinococcosis, lymphatic ﬁ lariasis, 
onchocerciasis, trachoma, dengue, yellow fever, rabies, soil-transmitted helminthiasis, and food-borne trematodiasis.
Table: Estimated global burden and deaths due to neglected diseases in 2010 and new therapeutic 
products approved or recommended in 2000–11
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therapeutics development and registration over the 
past 12 years, particularly for malaria, lends support to 
this claim. Pedrique and colleagues forecast that further 
increases in drug registrations for neglected diseases are 
to be expected.7
Second, although Pedrique and colleagues7 made 
great strides in reviewing readily available databases 
from major drug regulatory authorities, clinical trial 
registries, and WHO, notable omissions are three of 
the so-called BRICS countries—Russia, China, and 
South Africa. The investigators argue that data were 
not publicly available for either China or South Africa, 
but they “think it unlikely that new products would be 
registered only in these countries and nowhere else”. It’s 
possible that a systematic review of PubMed and other 
electronic databases would have identiﬁ ed additional 
therapeutic products aimed at neglected diseases. For 
instance, tribendimidine was registered in China in 
2004 with an initial indication against soil-transmitted 
helminthiasis.14,15 New clinical research has shown 
that tribendimidine has a broad spectrum of activity 
against nematode and trematode species, including 
the two liver ﬂ ukes Opisthorchis viverrini and Clonorchis 
sinensis.16,17 Third, from a methodological point of view, 
it is unclear why databases were only searched until 
Dec 31, 2011. However, we doubt that inclusion of more 
up-to-date data would alter Pedrique and colleagues’ 
main ﬁ ndings.7
Future studies should assess the research and 
development pipeline with a broader scope, including 
diagnostics, which is a truly neglected aspect of 
neglected diseases. In view of the massive scale-up of 
control and elimination eﬀ orts pertaining to neglected 
diseases,5 the pivotal importance of rapid, accurate, 
point-of-care diagnostic interventions cannot be 
emphasised enough.
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